Xiamen Amoytop Biotech Co., Ltd.
Clinical trials sponsored by Xiamen Amoytop Biotech Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill for fatty liver enters early human testing Results expected Feb 2027 (estimated)
- Can a new injection tame chronic hepatitis b? Results expected Mar 2027 (estimated)
- New drug ACT500 targets dual liver disease in early trial Results expected Mar 2027 (estimated)
- New lupus drug candidate begins first safety tests in humans Results expected Mar 2027 (estimated)
-
Could a simple injection prevent preeclampsia? early trial begins
Disease control CompletedThis early-stage trial tested the safety and tolerability of telpegfilgrastim injections in 18 non-pregnant women, including some with a history of preeclampsia. Researchers monitored side effects, drug levels in the blood, and immune markers. The goal is to see if the drug is sa…
Phase 1 • Sponsor: Xiamen Amoytop Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug for fatty liver disease first tested in healthy volunteers
Knowledge-focused CompletedThis early-stage study tested the safety of a new drug called ACT500 in 72 healthy Chinese adults. Participants received either the drug or a placebo, and researchers monitored side effects and how the drug moved through the body. The goal was not to treat disease but to gather e…
Phase 1 • Sponsor: Xiamen Amoytop Biotech Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC